OBJECTIVE: Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long-term behavioral and/or pharmacological interventions. METHODS: This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m2 ) who had lost ≥ 5% of initial weight during a 14-week low-calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks. RESULTS: At 24 weeks post randomization, more lorcaserin-treated than placebo-treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin-treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo (P = 0.010). However, at week 52, groups did not differ on either co-primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss (P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg (P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively (P = 0.318). CONCLUSIONS:Combined behavioral and pharmacological treatment produced clinically meaningful long-term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.
RCT Entities:
OBJECTIVE: Improving the maintenance of lost weight remains a critical challenge, which can be addressed by long-term behavioral and/or pharmacological interventions. METHODS: This study investigated the efficacy of combined behavioral and pharmacological treatment in facilitating weight loss maintenance (WLM) in 137 adults (86.1% female; 68.6% black; BMI = 37.0 ± 5.6 kg/m2 ) who had lost ≥ 5% of initial weight during a 14-week low-calorie diet (LCD) program (mean = 9.3 ± 2.9%). Participants were randomly assigned to lorcaserin (10 mg twice a day) or placebo and were provided 16 group WLM counseling sessions over 52 weeks. RESULTS: At 24 weeks post randomization, more lorcaserin-treated than placebo-treated participants maintained a ≥ 5% loss (73.9% vs. 57.4%; P = 0.033), and the lorcaserin-treated participants lost an additional 2.4 ± 0.8 kg versus a 0.6 ± 0.8 kg gain for placebo (P = 0.010). However, at week 52, groups did not differ on either co-primary outcome; 55.1% and 42.6%, respectively, maintained ≥ 5% loss (P = 0.110), with gains from randomization of 2.0 ± 0.8 kg and 2.5 ± 0.8 kg (P = 0.630), respectively. From the start of the LCD, groups maintained reductions of 7.8% and 6.6%, respectively (P = 0.318). CONCLUSIONS: Combined behavioral and pharmacological treatment produced clinically meaningful long-term weight loss in this group of predominantly black participants. Lorcaserin initially improved upon weight loss achieved with WLM counseling, but this advantage was not maintained at 1 year.
Authors: Rebecca L Pearl; Thomas A Wadden; Kelly C Allison; Ariana M Chao; Naji Alamuddin; Robert I Berkowitz; Olivia Walsh; Jena Shaw Tronieri Journal: Obes Surg Date: 2018-11 Impact factor: 4.129
Authors: Ariana M Chao; Thomas A Wadden; Jena Shaw Tronieri; Rebecca L Pearl; Naji Alamuddin; Zayna M Bakizada; Emilie Pinkasavage; Sharon M Leonard; Nasreen Alfaris; Robert I Berkowitz Journal: J Behav Med Date: 2018-07-31
Authors: Jena Shaw Tronieri; Thomas A Wadden; Ariana M Chao; Rebecca L Pearl; Naji Alamuddin; Robert I Berkowitz Journal: Ann Behav Med Date: 2019-03-01
Authors: Rebecca L Pearl; Thomas A Wadden; Ariana M Chao; Naji Alamuddin; Robert I Berkowitz; Olivia Walsh; Kelly C Allison; Jena Shaw Tronieri Journal: Behav Med Date: 2019-01-18 Impact factor: 3.104
Authors: Jena S Tronieri; Thomas A Wadden; Rebecca L Pearl; Robert I Berkowitz; Naji Alamuddin; Ariana M Chao Journal: Mindfulness (N Y) Date: 2020-09-18
Authors: Andrea Siebenhofer; Sebastian Winterholer; Klaus Jeitler; Karl Horvath; Andrea Berghold; Cornelia Krenn; Thomas Semlitsch Journal: Cochrane Database Syst Rev Date: 2021-01-17
Authors: Rebecca L Pearl; Thomas A Wadden; Jena Shaw Tronieri; Robert I Berkowitz; Ariana M Chao; Naji Alamuddin; Sharon M Leonard; Raymond Carvajal; Zayna M Bakizada; Emilie Pinkasavage; Kathryn A Gruber; Olivia A Walsh; Nasreen Alfaris Journal: Obesity (Silver Spring) Date: 2018-04-20 Impact factor: 5.002
Authors: Jena Shaw Tronieri; Thomas A Wadden; Nasreen Alfaris; Ariana M Chao; Naji Alamuddin; Robert I Berkowitz; Rebecca L Pearl Journal: Front Psychol Date: 2018-08-02